Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fierce Health vs Wisp

Fierce Health
Graded #411

Lower grade

vs+18.4
Wisp
Graded #59

Higher grade

The verdict

Wisp takes it — 75/100 to 56.6/100.

Wisp grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Wisp (hellowisp.com) is a US telehealth provider whose weight care vertical offers brand-name Wegovy, Zepbound, and Saxenda alongside a compounded sublingual semaglutide drops formulation at $225/month.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueWisp +50
33
83
Dose & formulationWisp +11
77
88
Clinical oversightWisp +20
62
82
Labs & monitoringWisp +1
52
53
FulfillmentFierce Health +9
75
66
Contract termsWisp +8
47
55
Fierce Health · left barWisp · right bar

The numbers

MetricFierce HealthWisp
WeighScore56.6/10075/100
GradeCC
Scorecard rank#411#59
Semaglutide$297/mo (3-month plan, compounded)$225/mo (compounded oral)
Tirzepatide$497/mo (3-month plan, compounded)$99/mo (starting dose, brand-name)
Coverage30 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
Fierce Health

Graded #411 · C

Strengths

  • 30-state service list spelled out in the Terms — buyers can verify eligibility before intake
  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer on every product page
  • Four GLP-1 programs (standard and microdose semaglutide and tirzepatide) — a broader ladder than peers
  • Microdose tier at $197/mo is one of the lower entry points we've seen

Where it loses points

  • No named 503A compounding pharmacy partner — only generic 'partner pharmacies' language
  • Operating LLC name not disclosed anywhere on the site
  • Tirzepatide weight-loss program ($497/mo) showing 'sold out or unavailable' across all plans at review time
  • Clinical provider network not named
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Wisp

Graded #59 · C

Strengths

  • Broad GLP-1 menu — branded injectables (Wegovy, Zepbound, Saxenda) plus a compounded sublingual option
  • LegitScript certified with named board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC)
  • Unusually candid about the sublingual option's limits, noting effectiveness in patients may vary

Where it loses points

  • Sublingual compounded semaglutide hasn't been tested in humans, per Wisp's own page — only the injectables have FDA efficacy data
  • Pharmacy partners not named
  • States served not listed publicly

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard